Latham & Watkins Advises on Annexon’s US$125 Million Underwritten Public Offering

Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, has announced the pricing of its previously announced underwritten public offering of 13,001,120 shares of its common stock at a price to the public of US$6.25 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 7,000,000 shares of common stock at a purchase price of US$6.249 per share, which equals the public offering price per share of the common stock less the US$0.001 exercise price per share of each pre-funded warrant.

Latham & Watkins LLP represented the underwriters in the offering with a capital markets team led by New York partner Nathan Ajiashvili and Orange County/ Bay Area partner Shayne Kennedy, with associates Katie Lovejoy, Alex Gulino, Richard Dacher, and Radley Gillis.